Anker, S.D., Butler, J., Filippatos, G., Shahzeb Khan, M., Ferreira, J.P., Bocchi, E., Böhm, M., Brunner-La Rocca, H.P., Choi, D.J., Chopra, V., Chuquiure, E., Giannetti, N., Gomez-Mesa, J.E., Janssens, S., Januzzi, J.L., Gonzalez-Juanatey, J.R., Merkely, B., Nicholls, S.J., Perrone, S.V., Piña, I.L., Ponikowski, P., Senni, M., Seronde, M.F., Sim, D., Spinar, J., Squire, I., Taddei, S., Tsutsui, H., Verma, S., Vinereanu, D., Zhang, J., Jamal, W., Schnaidt, S., Schnee, J.M., Brueckmann, M., Pocock, S.J., Zannad, F. and Packer, M. (2020) Baseline Characteristics of Patients with Heart Failure with Preserved Ejection Fraction in the EMPEROR-Preserved Trial. European Journal of Heart Failure, 22, 2383-2392.
https://doi.org/10.1002/ejhf.2064

has been cited by the following article:

• TITLE: Dapagliflozin and Spironolactone Improved Clinical Symptoms and CV Outcomes in Patient with HF Preserved Ejection Fraction (HFpEF) in Hard-to-Reach Rural African Population: A Case Series

  AUTHORS: Dominick Mkombozi Raphael, Abdu Hussein Mogella, Elias Edrick Mtalemwa, Beatrice Kabuka

  KEYWORDS: HFpEF, Spironolactone, Dapagliflozin, Africans Population

  JOURNAL NAME: Case Reports in Clinical Medicine, Vol.11 No.11, November 9, 2022

  ABSTRACT: Objective: To observe the benefit of mineralocorticoid receptor antagonist and sodium-glucose co-transport 2 inhibitor (SGLT2 inhibitor) in heart failure preserved ejection (HFpEF) in rural Tanzania. Background and Result: The use of spironolactone and dapagliflozin was shown to be effective in improving the clinical outcome and reducing CV hospitalization rate and CV mortality in patients with heart failure preserved left ventricular ejection fraction (HFpEF). This is the case presentation of one patient with HFpEF with diastolic dysfunction grade 3, obesity grade 3, Type 2 Diabetes, and Atrial Fibrillation (permanent). In the case of a 76-year-old female after previous ineffective treatment, the initiation of Spironolactone and Dapagliflozin led to a rapid and marked improvement in the clinical conditions. Diastolic dysfunction was improved from stage III to stage I. Moreover, the initiation of spironolactone and dapagliflozin therapy avoided a referral for surgical intervention and interrupted a long series of hospitalizations for acute HF and prevented CV death. Conclusion: Based on our experience, we conclude that the treatment with spironolactone and dapagliflozin allows for better treatment optimization with a positive impact on the control of clinical outcomes and preventing CV death and CV hospitalization in HFpEF and related comorbidities in the African population, which is underrepresented in most of the trials.